congresses-banner

The content contained is subject

PublicationView

Oral
Dato-DXd
WCLC 2024 | September 7-10, 2024
Lung Cancer
Datopotamab deruxtecan vs docetaxel in patients with non-small cell lung cancer: Final overall survival from TROPION-Lung01
Jacob Sands
Poster
I-DXd
WCLC 2024 | September 7-10, 2024
Lung Cancer
Exposure–response analyses to support phase 3 dose selection for ifinatamab deruxtecan (I-DXd) in patients with ES-SCLC
Narasimha M. Midde
Oral
I-DXd
WCLC 2024 | September 7-10, 2024
Lung Cancer
Ifinatamab deruxtecan (I-DXd) in extensive-stage small cell lung cancer (ES-SCLC): Interim analysis of IDeate-Lung01
Charles M. Rudin
Oral
T-DXd
WCLC 2024 | September 7-10, 2024
Lung Cancer
Trastuzumab deruxtecan monotherapy in pretreated HER2-overexpressing nonsquamous non-small cell lung cancer: DESTINY-Lung03 part 1
David Planchard
Poster
Dato-DXd, Valemetostat, Other/Multi
WCLC 2024 | September 7-10, 2024
Lung Cancer
Valemetostat and datopotamab deruxtecan in previously treated, advanced, unresectable, or metastatic nonsquamous NSCLC
Alexander Spira

footer